Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484714 | 1.00 | KIT (0.44) | KITKDM4ERECQLGRM1CYP3A4 | |
| SCHEMBL5482960 | 0.89 | GRM1 (0.51) | KITKDM4ERECQLGRM1L3MBTL1 | |
| SCHEMBL5482964 | 0.89 | GRM1 (0.51) | KITKDM4ERECQLGRM1L3MBTL1 | |
| SCHEMBL5483917 | 0.86 | GRM1 (0.42) | GRM1CYP3A4CYP2D6L3MBTL1PIK3CD | |
| SCHEMBL5480190 | 0.86 | GRM1 (0.42) | GRM1CYP3A4CYP2D6L3MBTL1PIK3CD | |
| SCHEMBL5480198 | 0.86 | GRM1 (0.42) | GRM1CYP3A4CYP2D6L3MBTL1PIK3CD | |
| SCHEMBL5483923 | 0.86 | GRM1 (0.42) | GRM1CYP3A4CYP2D6L3MBTL1PIK3CD | |
| SCHEMBL5481381 | 0.86 | GRM1 (0.42) | GRM1CYP3A4CYP2D6L3MBTL1PIK3CD | |
| SCHEMBL5481392 | 0.86 | GRM1 (0.42) | GRM1CYP3A4CYP2D6L3MBTL1PIK3CD | |
| SCHEMBL5486528 | 0.85 | GRM5 (0.44) | KITGRM1CYP3A4CYP2D6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | claimed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | KIT 2227/4885KDM4E 1679/4885RECQL 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.